Skip to main content
Top

12-09-2024 | Obesity | News

EASD 2024

Over 13% weight loss with new obesity drug amycretin

MedNet.nl: People without diabetes who took the new obesity drug amycretin lost 13% of their bodyweight in 12 weeks. Amycretin was shown to be safe and reliable in this first study of people taking the amylin/GLP-1 receptor agonist.

Related topics

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more